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Summary 
A three drug preventive regimen for the treatment of children exposed to multidrug-
resistant tuberculosis was well tolerated with limited toxicity. Few children developed 
tuberculosis or died. This regimen should be seen as a safe and effective option. 
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ABSTRACT 
 
Background 
Evidence is limited to guide the management of children exposed to multidrug-resistant 
(MDR) tuberculosis (TB). We aimed to study the tolerability and toxicity of a standard 
preventive therapy regimen, given to children exposed to infectious MDR-TB, and explore 
risk factors for poor outcome. 
 
Methods 
Prospective cohort study: Western Cape, South Africa. Children <5 years old, or HIV-positive 
children <15, were recruited from May 2010 through April 2011 if exposed to an ofloxacin-
susceptible, MDR-TB source case.  Children were started on preventive therapy as per local 
guidance: ofloxacin, ethambutol and high-dose isoniazid for six months. Standardized 
measures of adherence and adverse events were recorded; poor outcome was defined as 
incident TB or death from any cause. 
 
Results 
186 children were included, median age 34 months (inter-quartile range: 14-47). Of 179 
children tested for HIV, 9 (5.0%) were positive. Adherence was good in 141 (75.8%) children. 
Only 7 (3.7%) children developed Grade 3 adverse events. One child (0.5%) died and six 
(3.2%) developed incident TB during 219 patient years of observation time. Factors 
associated with poor outcome were: age <1 year (rate ratio: 10.1; 95%CI: 1.65-105.8; 
p=0.009), HIV-positive status (rate ratio: 10.6; 95%CI: 1.01-64.9; p=0.049), exposure to 
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multiple source cases (rate ratio: 6.75; 95%CI: 1.11-70.9; p=0.036) and poor adherence (rate 
ratio: 7.50; 95%CI: 1.23-78.7; p=0.026). 
 
Conclusions 
This three-drug preventive therapy regimen was well tolerated and few children developed 
TB or died if adherent to therapy. The provision of preventive therapy to vulnerable children 
following exposure to MDR-TB should be considered.
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INTRODUCTION 
 
For a child to develop tuberculosis (TB), they must first be exposed to an infectious TB 
source case, then become infected and finally progress to disease.[1] Children at the highest 
risk of progressing from infection to disease are young (<5 years)[2] and HIV-positive 
children.[3] If children with Mycobacterium tuberculosis infection are given effective 
therapy to prevent the progression to disease, many children will be spared TB disease 
episodes. This has clinical implications for the individual, reducing morbidity, mortality and 
avoiding lengthy, unpleasant and potentially costly treatment with associated adverse 
events. It also has implications for the community as children provide a reservoir for future 
disease, with propagation of the epidemic by those children who develop infectious TB. The 
first trials of isoniazid as preventive therapy for TB were carried out over fifty years ago,[4] 
and isoniazid has been demonstrated to reduce the risk of progression from infection to 
disease in HIV-positive and HIV-negative children following exposure to drug-susceptible 
TB.[5-6] The majority of international agencies and National TB Programs therefore advise 
providing children less than five years and all HIV-positive children with isoniazid daily for six 
months following exposure to an infectious case of drug-susceptible TB.[7] 
 
Multidrug-resistant (MDR) TB is caused by M. tuberculosis resistant to at least rifampin and 
isoniazid.[8] Following exposure to a source case with MDR-TB it is unclear how children 
should be managed.[9] Although concordance between putative source cases and child 
contacts is not complete, many clinicians are uncomfortable treating a child exposed to an 
MDR organism with isoniazid. Cases have been reported of children exposed to MDR-TB 
developing TB disease on isoniazid preventive therapy.[10-11] The Centers for Disease 
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Control identified the need for a preventive therapy trial for contacts of MDR-TB in 
1992.[12] Since then numerous international agencies and experts have also recommended 
that the investigation of MDR-TB preventive therapy should be a global public health 
priority.[13-16]  However, no trials have been conducted to date. 
 
One of the major concerns regarding the provision of preventive therapy in children using 
drugs other than isoniazid is potential toxicity in healthy children. In the treatment of MDR-
TB disease, the risk-benefit ratio of potentially toxic therapy is relatively clear. In contrast, 
this risk-benefit ratio is altered when using potentially toxic preventive therapy in children 
who are currently well, but are at risk of developing future disease. Particular caution has 
been exercised regarding the use of the fluoroquinolones in children, based on early animal 
model data showing damaging effects to the cartilage growth of young beagles.[17] There 
are limited published data regarding the efficacy, tolerability and toxicity of preventive 
therapy regimens given to children exposed to MDR-TB. 
 
The World Health Organization (WHO) estimates that there were 650,000 prevalent cases of 
MDR-TB in 2010.[18] A previous MDR-TB contact study suggested that in a setting with a 
high burden of TB there are nearly two child contacts for each adult TB source case.[19] As 
many as a million children could therefore be exposed to MDR-TB globally each year, many 
of whom, in the absence of effective preventive therapy, will go on to develop MDR-TB 
disease. While treatment outcomes for MDR-TB disease are good with tailored 
individualized therapy in children, the treatment in children is complex, long and associated 
with significant adverse events.[20] Appropriate drugs and child-friendly formulations are 
limited and interactions between antiretroviral and anti-TB drugs are common.[21-22] MDR-
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TB is expensive to treat and often requires prolonged hospitalization.[23] We therefore 
aimed to study the tolerability and toxicity of a standard MDR-TB preventive therapy 
regimen, given to children following documented exposure to adults with MDR-TB, and 
determine how many children develop poor outcomes. 
 
METHODS 
 
Setting 
The Western Cape province of South Africa had a TB notification rate of 976 per 100,000 in 
2009.[24] Among children with culture-confirmed TB at the regional referral hospital for 
pediatric drug-resistant TB, Tygerberg Children’s Hospital (TCH), 8.9% had MDR-TB during 
2007-2009.[25] Children exposed to an infectious case of MDR-TB are routinely referred to a 
specialist pediatric drug-resistant TB clinic at TCH, or to community outreach clinics served 
by a specialist from this hospital.  
 
Standard of Care 
Following exclusion of TB disease through history, clinical examination, plain film chest 
radiology (with mycobacterial culture in the presence of symptoms or abnormal chest 
radiography), children who were less than five years of age or HIV-positive, with significant 
exposure to an infectious (sputum smear or culture positive) pulmonary MDR-TB source 
case, were  routinely given a regimen of MDR-TB preventive therapy, irrespective of 
tuberculin skin test (TST) result, as advised by provincial guidelines. Significant exposure was 
defined as living with or having regular daily interaction with the MDR-TB source case. If the 
source case had MDR-TB with susceptibility to the fluoroquinolones, the child was given 
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ofloxacin (15-20mg/kg daily; the only fluoroquinolone available for children at the time), 
ethambutol (20-25mg/kg daily) and isoniazid (15-20mg/kg daily) for 6 months. Children 
were routinely evaluated at two, four, six and twelve months, at TCH or the community 
outreach sites, through clinical evaluation and chest radiography. Drugs were dispensed at 
local community TB clinics, on either a daily, weekly or monthly basis, depending on clinic 
and patient preference. HIV testing was offered to all child TB contacts following informed 
consent from the parent or legal guardian, with assent from the child where appropriate. An 
ELISA was used in children older than 18 months or DNA PCR if younger or breast-fed. 
Combination antiretroviral therapy (cART) was routinely initiated in all HIV-positive children 
following appropriate evaluation. TST was completed by TB clinic personnel by injecting two 
tuberculin units intradermally (purified protein derivative RT23, Statens Serum Institute) 
with results read at 48-72 hours; an induration of ≥10mm (or ≥5mm if HIV-positive) was 
regarded as positive.  
 
Study population and eligibility 
All children evaluated at TCH or community outreach clinics were eligible if they had been in 
significant contact with an infectious case of pulmonary MDR-TB (‘the source case’), within 
the preceding six months and if the drug susceptibility test (DST) of the isolate from the 
source case showed susceptibility to ofloxacin. Children were enrolled if they had started 
preventive therapy from May 2010 through April 2011. Children were recruited following 
written, informed consent from their caregivers with assent from the child where 
appropriate. The study was approved by the Stellenbosch University and London School of 
Hygiene and Tropical Medicine Ethics Committees.  
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Data collection 
Children were seen by the study team at their routine clinical appointments, as well as at 
any additional, unscheduled visits. At the initial interview, following screening for TB 
disease, data were collected regarding demographic and clinical details. At follow-up visits, 
after clinical assessment, parents/caregivers were interviewed concerning adherence and 
potential drug-related adverse events using a structured questionnaire. In addition, during 
the first half of 2012, children were traced and either recalled to clinic or visited at their 
local clinic or home by the study team. Where this was not possible, local clinics and families 
were contacted to confirm that the child was clinically well and was gaining weight. The 
date of this final interaction was recorded. Follow-up time for the children, therefore, was a 
minimum of 12 months and up to 24 months in some children.  
 
Adherence was measured in two ways at each study visit. The first was a three-day recall 
and the second a 30-day visual analogue score. Each of these two measures was scaled to 
give a score out of thirty. Scores derived from both measures from each visit were added to 
determine a total ‘score’ for the whole period on treatment.[26-27] If this was above 80% of 
a possible maximum then adherence was recorded as good with scores less than 80% as 
poor.[28] Local clinics were also contacted to verify medication uptake. In cases of 
discrepancy, adherence was reported as being poor. Adverse events to medications were 
categorized using the Division of Microbiology and Infectious Diseases (DMID) system.[29] 
(Table 1). As arthralgia is not categorized in this classification we allocated five grades 
consistent with the DMID classification. If old enough to co-operate, visual toxicity was 
evaluated with Ishihara charts. Parental impression of visual function was used for children 
who could not be evaluated in this way. Study outcomes were: well at the end of the 
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observation period, death of any cause and incident TB disease. Standardized research 
definitions were applied to classify incident TB disease in children [30]; confirmed and 
probable disease were considered incident TB. Where patients were lost to follow-up their 
censoring date was recorded as the last interaction with the study team. A combined 
endpoint of incident TB and/or death was classified as poor outcome. 
 
Data analysis 
Data were double-entered and checked for entry errors. Data were analyzed using STATA 
software (version 11; Stata Corp, College Station, TX). Cohort analysis was undertaken to 
examine factors associated with poor outcome. Time of entry into the cohort was the date 
of recruitment and time exiting the cohort was the date of death, diagnosis of incident TB or 
date of last contact with the study team. Due to the small number of events, exact Poisson 
analysis was undertaken for a limited number of predetermined characteristics of the child 
and treatment, with rate ratios (RR), 95% confidence intervals (CI) and p-values calculated.  
 
RESULTS 
 
Of 245 children initially eligible, 186 were included as contacts of 164 MDR-TB source cases. 
Of the children excluded, 12 were brought by an adult who could not provide legal consent, 
for two children consent was not given, 29 were contacts of MDR-TB source cases with 
additional resistance to ofloxacin and in the remainder (n=16), although the source case was 
said to have MDR-TB at the initial assessment, and the child was initially given MDR-TB 
preventive therapy, the adult was subsequently confirmed to have resistance to only either 
isoniazid or rifampin. For the children included, the median age was 34 months (inter-
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quartile range [IQR]: 14-47), and 102 (55%) were boys (Table 2). The mean weight-for-age z-
score was 0.59 standard deviations below the reference population. Of 179 children tested 
for HIV, 9 (5.0%) were positive. Adherence was good in 141 (75.8%) children and only two 
children were lost to follow-up before twelve months. 
 
Adverse events are demonstrated in Table 3, with all Grade 3 adverse events shown in Table 
4. Of the six children (3.2%) who experienced a Grade 3 adverse event, three were 
associated with inadvertent overdosing of ofloxacin. No adverse events necessitated the 
discontinuation of preventive therapy and all resolved without intervention. The most 
common Grade 2 or higher adverse events were loss of appetite and nausea (12 children; 
6.2%), itchy skin (9 children; 4.7%), disturbance of sleep or mood (7 children; 3.6%) and skin 
rash (7 children; 3.6%).  
 
Over a total of 219 patient years of observation time one child died (0.5%; most likely of 
sudden infant death syndrome) and six developed incident TB (3.2%). All had probable 
disease. (Table 5) The rate for poor outcome was 31.9 outcomes (95%CI: 12.8-65.9) per 
1000 years of patient follow up. Factors associated with increased risk of poor patient 
outcome (Table 6) were: age less than one year (rate ratio [RR]: 10.1; 95%CI: 1.65-105.8; 
p=0.009), HIV positivity (RR: 10.6; 95%CI: 1.01-64.9; p=0.049), exposure to multiple source 
cases (RR: 6.75; 95%CI: 1.11-70.9; p=0.036) and poor adherence (RR: 7.50; 95%CI: 1.23-78.7; 
p=0.026). 
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DISCUSSION 
 
We demonstrate that the provision of MDR-TB preventive therapy in child MDR contacts is 
well tolerated, associated with few clinically significant adverse events, and results in a low 
rate of incident TB or death. The three cases of Grade 3 toxicity, associated with inadvertent 
overdosing of ofloxacin, is concerning. In South Africa, at the time our study was conducted, 
ofloxacin was available in two formulations: 200mg and 400mg. Medications are frequently 
dispensed as loose tablets within a re-sealable packet with the number of tablets to be 
taken written on the outside. If the packet is refilled with a different strength of tablet, 
confusion can occur. We noted only one Grade 2 or higher episode of joint, muscle or bone 
pain. Given the historical concerns regarding fluoroquinolone use in children, these findings 
are reassuring. We also observed no hepatotoxicity or visual problems.  
 
During over 200 patient years of follow-up, only one child died and six developed incident 
TB. It is likely that the child that died did not develop TB but died of some other illness. Of 
the six children who developed incident TB, four were not given the prescribed medications 
conscientiously and no children given medications under daily observed therapy developed 
TB. Risk factors for poor outcome included young age (<12 months) and HIV infection. These 
risk factors are well described in the drug-susceptible pediatric TB literature[2-3] and should 
prompt enhanced vigilance in these especially vulnerable populations. That children 
exposed to multiple source cases had higher rates of poor outcome is interesting. It may be 
that having multiple source cases increases the risk of mycobacterial transmission or it may 
be that highly virulent strains circulate in some households. It may be that genetic factors 
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render certain families more susceptible to TB or it may be that social factors such as 
crowding, alcohol, drugs, nutrition or adherence influence both the adults and the children.  
 
Few studies have previously assessed preventive therapy for child contacts of MDR-TB and 
no randomized controlled trials have been conducted.[31] One study in Cape Town 
examined 105 children; 41 were given a multidrug preventive regimen tailored to the drug 
susceptibility test pattern of the source case isolate.[19] Only two of the 41 treated patients 
(5%) developed TB disease compared to 13 (20%) observed without treatment. A study in 
Rio de Janeiro followed 218 adult and child contacts of MDR-TB; 45 had been given 
isoniazid.[32] There was no protective effect of the isoniazid. A final study in Chuuk, 
Federated States of Micronesia, examined 110 infected adult and child MDR-TB contacts, 
given a twelve-month individually tailored multi-drug preventive regimen under directly 
observed therapy. No patients given preventive therapy developed TB.[33] Guidelines 
vary[34-36] as do expert opinion[37-38] and published practice.[11, 39-42]  Some agencies 
advise careful follow-up alone,[7, 43] some recommend isoniazid,[44] some suggest two 
drugs to which the index case’s TB strain is susceptible,[12] and some advocate specialist 
referral.[45] A Delphi survey of experts was unable to reach consensus,[46] and two 
systematic reviews concluded that there was not enough evidence to inform policy 
development regarding MDR-TB preventive treatment.[47] A report from the European 
Centre for Disease Prevention and Control suggest that either tailored preventive therapy 
with close follow-up or close follow-up alone are acceptable options in the absence of 
better data.[13] 
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This is the largest study to date documenting the effect of a standard preventive therapy 
regimen for children exposed to MDR-TB. Follow-up was good and both adherence and 
adverse events were carefully documented. However, our study had several limitations. As 
this was an observational study without a control group, it is not possible to conclude with 
certainty that this regimen is effective. It is possible that the number of children developing 
TB could have been similar had they been given isoniazid alone or even no medications at 
all. However, the pre-chemotherapy data do not support this argument. In the absence of 
preventive therapy, it has been shown that up to 50% of M. tuberculosis-infected children 
less than twelve months of age developed TB disease.[2] The figure is 20-30% for children 
aged between one and two years and 5% for children aged between two and five years. 
Although only 40% of our cohort was TST positive, we would still expect to see far higher 
numbers of children developing TB if the regimen was not effective. In addition, the 
evidence that poor adherence to preventive therapy was strongly associated with poor 
outcome adds support to the argument that this regimen is effective in reducing the risk of 
progression from infection to disease. We included children irrespective of TST status, 
consistent with national and provincial guidelines. The rationale for this is that TST is not a 
highly sensitive test for M. tuberculosis infection, especially in the young infant, HIV-positive 
children and malnourished children nor is it highly specific in settings where BCG is routinely 
given at birth such as ours. By only including TST positive children a number of infected 
children would therefore have been excluded. Also, if a TST is negative at the time of initial 
assessment, there is a chance that the child may have been infected but may only convert 
their test later. Rather than use a two stage protocol with all children started on preventive 
therapy, which is then stopped if a second TST at follow-up is negative, the local policy is for 
all exposed children to be treated. We employed these operational entry criteria in our 
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study. It could, therefore, be argued that some of the children in the study did not require 
treatment. As mycobacteria were not isolated from any of the children that developed TB, 
we were unable to determine if this preventive therapy regimen resulted in increased rates 
of fluoroquinolone resistance. This is a potential concern and should be evaluated in future 
studies. A final limitation of the study is the duration of follow-up. All children were 
followed for a minimum of twelve months with some followed for 24 months. Although the 
vast majority (>90%) of children who develop disease do so within twelve months of 
infection,[4, 19] it is accepted that some children might progress to disease after the period 
of observation.  
 
To conclusively determine the utility of preventive therapy for child contacts of MDR-TB, a 
clinical trial is warranted, one in which children are randomly and blindly assigned to either 
a fluoroquinolone-containing multi-drug regimen or to isoniazid alone. However, until that 
time, clinicians will continue to be confronted by children exposed to MDR-TB. We have 
demonstrated this regimen to be well tolerated and associated with limited toxicity. Also, 
clinicians should be confident when managing a child exposed to MDR-TB that providing this 
preventive therapy regimen results in reassuringly low rates of TB or death. 
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Table 1. Classification of adverse events used in children receiving multidrug-resistant tuberculosis preventive therapy 
Adverse event 
 
 
Grade 0 Grade 1 
 
Grade 2 Grade 3 Grade 4 
Joint, muscle or 
bone pain 
 
No adverse event Pain but no interference with 
function or movement 
Moderate pain, affecting function 
but able to carry out normal 
activities 
Severe pain limiting activities Disabling pain – unable to 
carry out activities 
Skin Rashes 
 
 
No adverse event Small areas of redness /rash Dry peeling or widespread rash Wet peeling, ulcers or 
urticaria 
Severe, widespread rash, 
necrosis needing 
hospitalization 
Itchy skin 
 
 
No adverse event Slight itching in localized 
areas 
Severe itching in localized areas Widespread itching over 
entire body 
Uncontrollable scratching 
needing hospitalization 
Headache 
 
 
No adverse event Mild – does not need 
treatment 
Transient/moderate – needs non-
narcotic treatment 
Severe –responds to narcotics Intractable pain 
Sleeping/mood 
 
 
No adverse event Mild anxiety Moderate anxiety or problems 
getting to sleep 
Severe anxiety, problems 
getting to sleep or repeated 
waking 
Psychosis, unable to sleep 
for more than an hour 
Lethargy 
 
 
No adverse event Activity Reduced but for <48 
hours 
Slightly irritable or slightly subdued Very irritable or lethargic Inconsolable or obtunded 
Visual problems 
 
 
No adverse event None Blurred vision or minor visual 
disturbance lasting less than 1 hour 
Repeated episodes of blurring 
or visual disturbances which 
resolve 
Permanent decrease in 
visual acuity or field defect 
Vomiting 
 
 
No adverse event 1 episode in 24 hours 2-3 episodes in 24 hours 4-6 episodes in 24 hours >6 episodes in 24 hours or 
needing hospitalization 
Diarrhea 
 
 
No adverse event Slight change in consistency 
or frequency of stool 
Liquid stool Liquid stool >4x normal 
frequency for child 
Liquid stool >8x normal 
frequency for child 
Jaundice 
 
 
No adverse event Jaundice detectable clinically 
– bilirubin 1.1 - 1.5 x ULN 
Obvious clinical jaundice – bilirubin 
1.6 – 2.5 x ULN 
Severe jaundice – bilirubin 2.6 
– 5 x ULN 
Hospitalization – bilirubin 
>5x ULN 
Loss of 
appetite/nausea 
 
No adverse event Mild – still eating/drinking 
well 
Moderate - decreased appetite Severe – little food taken No solid or liquid food taken 
ULN: Upper limit of normal (as determined by reference range for age of child and assay used)
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Table 2. Baseline characteristics of children exposed to a multidrug-resistant tuberculosis source 
case and placed on preventive therapy (n=186) 
Characteristic 
 
Description Result 
Median age in months (IQR)  34 (14-47) 
Male gender (%)  102 (54.8) 
Ethnicity (%) South African Colored 100 (53.8) 
Xhosa 84 (45.2) 
White 1 (0.5) 
Other 1 (0.5) 
Mean weight-for-age z-score (SD; n=182)  -0.59 (1.51) 
Mean height-for-age z-score (SD; n=142)  -1.00 (1.35) 
TST positive (%; n=183)  73 (40.0) 
Evidence of BCG scar (%; n=181)  145 (80.1) 
Multiple MDR-TB source cases (%; n=176)  49 (27.8) 
HIV-positive (%; n=179)  9 (5.0) 
On cART at start of preventive therapy (%; 
n=9) 
 8 (88.9) 
Type of medication delivery (%) DOT at clinic 20 (10.8) 
DOT by treatment support worker 3 (1.6) 
Weekly supply for parents to 
administer 
141 (75.8) 
Monthly supply for parents to 
administer 
16 (8.6) 
Other 6 (3.2) 
IQR= Interquartile range; SD = standard deviation; TST = tuberculin skin test; BCG = Bacillus 
Calmette–Guérin; MDR-TB = multidrug-resistant tuberculosis; HIV = human immunodeficiency virus; 
cART = combination antiretroviral therapy; DOT = directly observed therapy 
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Table 3. Summary of cumulative most severe adverse event in children receiving six months of multidrug-resistant tuberculosis preventive therapy 
(n=186) 
Adverse event Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Total 
Joint, muscle or bone pain* 178 5 1 0 0 184 
Skin Rashes 140 40 6 0 0 186 
Itchy skin 147 33 6 0 0 186 
Headache* 153 3 2 0 0 158 
Sleeping/mood 170 8 4 4 0 186 
Lethargy 183 3 0 0 0 186 
Visual problems 186 0 0 0 0 186 
Vomiting 155 30 1 0 0 186 
Diarrhea 170 15 1 0 0 186 
Jaundice 186 0 0 0 0 186 
Loss of appetite/nausea 150 15 19 2 0 186 
*Total not 186 as some parents stated that they could not determine if the child had experienced the adverse event 
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 Table 4. Characteristics of children developing Grade 3 adverse events (n=6) on MDR-TB preventive therapy  
Age  
 
 
Gender HIV 
status 
Adverse event(s) Details 
6 months Girl Negative Loss of appetite Appetite reported as normal at the two month appointment, Grade 2 at the four month 
appointment and Grade 3 at the six month appointment 
Mother reported that some of the loss of appetite might have been due to teething 
Preventive therapy continued throughout 
 
14 months Boy Negative Loss of appetite Child reported to have Grade 3 appetite loss at two months, then none at 4 months but Grade 1 
at six months 
Preventive therapy continued throughout 
 
25 months Boy Negative Insomnia and 
hallucinations 
At the two month appointment child reported not sleeping due to hallucinations 
Child had been prescribed 300mg ofloxacin but inadvertently given 600mg by clinic staff 
Preventive therapy continued at correct dose and symptoms resolved 
 
38 months Girl Negative Insomnia Mother reported severe insomnia at the two month appointment but stated that the problem 
had been evident prior to starting the preventive therapy 
Preventive therapy continued and sleeping improved 
 
38 months Girl Negative Insomnia and 
hallucinations 
At the two month appointment the mother reported the child to be having hallucinations and 
sleep problems 
Child had been prescribed 300mg ofloxacin but inadvertently given 600mg by clinic staff 
Symptoms resolved on correct dosage  
 
45 months Boy Negative Insomnia At the two month appointment the mother reported that the child did not sleep at all 
Child had been prescribed 300mg ofloxacin but inadvertently given 600mg by clinic staff 
Symptoms resolved on correct dosage 
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Table 5. Mortality and incident tuberculosis in children given preventive therapy for multidrug-resistant tuberculosis (n=7) 
 
Age at 
cohort 
entry 
 
Gender TST 
result 
HIV 
status 
Source 
case 
Outcome Time to 
outcome 
Adherence Details 
12 days Boy No 
result 
Negative Mother’s 
cousin 
Died 3 weeks Poor Baby died after three weeks in what appeared to 
be sudden infant death syndrome. No doses of 
preventive therapy given  
 
2 months Boy 0mm Negative Mother TB 10 months Poor Developed TB ten months after initially being 
seen having received only intermittent preventive 
therapy 
 
3 months Boy 0mm Positive Mother  TB 9 months Poor Child not given preventive therapy after the point 
at which his mother was admitted to hospital 
(after 3 months of therapy) 
 
9 months Girl 0mm Positive Mother TB 6 months Poor Poor adherence following the death of the 
mother which happened soon after the child was 
initially evaluated 
 
10 months Girl 0mm Negative Mother TB 2 months Good Developed TB after two months on preventive 
therapy, with adherence reported to be good 
 
34 months Girl 10mm Negative Mother TB 2 months Poor Preventive therapy prescribed but no doses given 
by parents 
 
51 months Boy 15mm Negative Aunt TB 10 months Good Developed TB four months after stopping 
preventive  therapy, reported to have been given 
with good adherence 
 
TST: tuberculin skin test; HIV: human immunodeficiency virus; TB: tuberculosis      
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Table 6. Assessment of risk factors for poor outcome (death or incident tuberculosis disease) in children exposed to multidrug-resistant tuberculosis and 
treated with a preventive therapy regimen (n=186) 
 
  Number of 
events 
Years of 
observation 
Incidence rate with 95% CI (events 
per 1000 person years) 
 
Rate Ratio (95% CI) p-value 
Age >12 months 2 175.5 11.4 (1.4-41.1) 1  
 0-12 months 5 43.5 114.9 (37.3-268.2) 10.1 (1.65-105.8) 0.009 
Gender Female 3 95.6 31.4 (6.5-91.7) 1 - 
 Male 4 123.4 32.4 (8.8-83.0) 1.03 (0.17-7.05) 1.00 
TST  Negative 4 132.1 30.3 (8.3-77.5) 1.0 - 
 Positive 2 84.8 23.6 (2.9-85.2) 0.78 (0.07-5.43) 1.00 
Source cases Single 2 152.4 13.1 (3.28-52.5) 1.0 - 
 Multiple 5 56.4 88.6 (36.9-213.0) 6.75 (1.11-70.9) 0.036 
HIV status Negative 5 201.5 24.8 (8.1-579.1) 1.0 - 
 Positive 2 7.6 263.8 (31.9-950.6) 10.6 (1.01-64.9) 0.049 
Adherence Good 2 164.3 12.2 (1.5-44.0) 1.0 - 
 Poor 5 54.8 91.3 (29.6-212.9) 7.50 (1.23-78.7) 0.026 
Type of delivery Daily observed therapy 0 31.5 0 (0-117.1) - - 
 Other 7 187.6 37.3 (15.0-76.8) - 0.68 
CI = confidence interval; TST = tuberculin skin test; HIV = human immunodeficiency virus 
